T1	Participants 73 127	patients with severe chronic congestive heart failure:
T2	Participants 263 321	patients with moderate to severe congestive heart failure.
T3	Participants 591 766	1,068 patients enrolled in a survival study of class III or IV heart failure at the time of double-blind randomization to milrinone, a phosphodiesterase inhibitor, or placebo.
